Model correctly identified cancer types in most cases in the test cohort and the independent validation cohort.

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

At AACR, Revolution Medicines presented more eye-catching data about its KRAS-targeting treatment, and Anthony Letai declared ...

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses ...

You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening at the American ...

AACR 2026 saw thousands gathered in San Diego, California, where major progress in cancer research was revealed.

Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...

National Cancer Institute Director Anthony Letai, M.D., Ph.D., has attempted to fight back against the “misinformation” ...

New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion ...

The AACR 2026 meeting in San Diego showcased major advances in targeted therapies, immunotherapy, and cancer vaccines, with data suggesting potential shifts in clinical practice. Highlights included ...

At the AACR 2026 meeting, researchers unveiled AI foundation models and clinical tools poised to transform cancer research and precision oncology. Presentations highlighted successes such as improved ...

Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai, its ...